- Home
- PRQR vs ABEO Comparison
PRQR vs ABEO Comparison
Compare PRQR & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRQR | ABEO |
|---|---|---|
| Founded | 2012 | 1974 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.7M | 281.0M |
| IPO Year | 2014 | 1980 |
Fundamental Metrics
Financial Performance| Metric | PRQR | ABEO |
|---|---|---|
| Price | $2.34 | $5.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $8.14 | ★ $18.20 |
| AVG Volume (30 Days) | 348.1K | ★ 2.8M |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.29 |
| Revenue | ★ $18,859,556.00 | $400,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $324.71 |
| P/E Ratio | ★ N/A | $3.94 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.07 | $3.93 |
| 52 Week High | $3.97 | $7.54 |
Technical Indicators
Market Signals| Indicator | PRQR | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 53.26 | 56.25 |
| Support Level | $2.10 | $4.37 |
| Resistance Level | $2.40 | $5.17 |
| Average True Range (ATR) | 0.17 | 0.32 |
| MACD | 0.02 | 0.12 |
| Stochastic Oscillator | 89.49 | 65.80 |
Price Performance
Historical ComparisonAbout PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.